1Clinical Pipeline

2Emerging pipeline

Transforming Drug Discovery for the Next Wave of Medicines

BXCL701 Revolutionizing drug development and translation research in Immuno-Oncology (IO)

BXCL501 Treating the Symptoms of Neuropsychiatric and Neurodegenerative Diseases

BXCL702 Developing the drug as mono-therapy and in combination with immune-checkpoint inhibitors

Learn more

The Healing Power of Science

Medicines that change lives



Targeting immuno-oncology and neuroscience disorders with significant unmet medical need



Proprietary drug re-innovation approach to other underserved areas in oncology and neuroscience


Higher Probability

Generating first in class drug candidates with a higher probability of clinical and regulatory success


Therapeutic Benefit

Potential to provide significant therapeutic benefit to the patients who need close medical attention

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company engaged in the development and advancement of the next wave of medicines.The company is focused on a drug re-innovation approach to develop therapeutic candidates with a high probability of clinical & regulatory success


Press Coverage

21 April 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

View all Press Coverages

News Releases

6 October 2017

BioXcel Therapeutics to Present Data on [BXCL701] at the 24th Annual Prostate Cancer Foundation Scientific Retreat

View all News Releases